Teva Recalls Prazosin Hydrochloride Capsules
Analysis based on 10 articles · First reported Oct 29, 2025 · Last updated Oct 31, 2025
The recall by Sun Pharma of a widely used blood pressure medication due to potential carcinogens could lead to a temporary dip in investor confidence in the pharmaceutical sector, particularly for companies with similar manufacturing processes. It also highlights the ongoing regulatory scrutiny by the United States — Food and Drug Administration on drug safety, potentially increasing compliance costs for other drugmakers.
Sun Pharma, along with distributor Cencora, has initiated a voluntary nationwide recall of over 580,000 bottles of prazosin hydrochloride capsules. This blood pressure medication, also prescribed for PTSD-related sleep disturbances, was found to contain nitrosamine impurities, specifically 'N-nitroso Prazosin impurity C,' which are considered potentially cancer-causing. The United States — Food and Drug Administration classified this as a Class II risk, indicating that exposure may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. While no adverse effects have been reported, Sun Pharma has advised patients to consult their pharmacists and doctors, and not to stop medication abruptly. This event follows similar recalls by other companies like Pfizer, Merck & Co., Novartis — Sandoz, and Rising Pharmaceuticals due to nitrosamine contamination.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard